12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MNK-155: Phase III data

A double-blind, U.S. Phase III trial in about 400 patients with moderate to severe acute pain following a unilateral first metatarsal bunionectomy showed that a loading dose of 3 tablets of oral MNK-155 followed by 2 tablets every 12 hours for 48 hours met the primary endpoint of reducing SPID48...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >